AvroBio Inc

NASDAQ:AVRO   3:59:59 PM EDT
14.04
+0.01 (+0.07%)
Products, Regulatory

AVROBIO Announces New Positive Clinical Data And Preclinical Data, As Well As Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

Published: 11/17/2020 12:54 GMT
Avrobio Inc (AVRO) - Avrobio Announces New Positive Clinical Data and Preclinical Data, As Well As Expanded Leading Lysosomal Disorder Gene Therapy Pipeline.
Avrobio - Three Months Post-gene Therapy, First Patient in Gaucher Trial Shows Reductions in Toxic Metabolite Plasma Lyso-gb1 Compared to Baseline.
Avrobio - Three Months Post-gene Therapy, First Patient in Gaucher Trial Shows Reductions in Plasma Chitotriosidase As Compared to Baseline.
Avrobio - Ongoing Fabry Disease Trials Continue to Demonstrate Sustained Durability, With First Patient Out 3.5 Years.
Avrobio - One Year Post-gene Therapy, First Patient in Cystinosis Trial Remains Off Cysteamine.
Avrobio - Clinical Trial Recruitment Gaining Momentum With Five New Patients Expected to Be Dosed, Enrolled Or Consented in 4q 2020.